---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-095513"
form_type: "8-K"
ticker: "DMII"
cik: "0002040475"
company_name: "Drugs Made In America Acquisition II Corp."
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:59:00.416309+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Drugs Made In America Acquisition II closes $500M IPO and $12M private placement

## Summary
- IPO of 50M units at $10 each grossed $500M; units trade on Nasdaq (DMIIU).
- Private placement of 1.2M units to sponsor and Cantor Fitzgerald raised $12M.
- $500M deposited into trust account; company has 24 months to complete initial business combination.
- Balance sheet: $1.58M cash, $17.5M deferred underwriting liability, $17.2M accumulated deficit.
- Auditor includes going concern qualification due to mandatory liquidation if no business combination within 24 months.

## SEC filing metadata
- accession: 0001213900-25-095513
- form_type: 8-K
- ticker: DMII
- cik: 0002040475
- company_name: Drugs Made In America Acquisition II Corp.
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2040475/000121390025095513/0001213900-25-095513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2040475/000121390025095513/ea0259662-8k_drugs2.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-095513
- JSON: https://secwatch.observer/filing/0001213900-25-095513.json
- Plain text: https://secwatch.observer/filing/0001213900-25-095513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.